PRODUCT
CytomX Continues Phase I ADC Study After Patient Death
CytomX; CX-2051; Phase I; ADC; colorectal cancer; patient death; acute kidney injury; clinical trial; safety; FDA; trial continuation
PureTech Spins Out Celea Therapeutics to Advance IPF Drug Candidate
PureTech; Celea Therapeutics; spin-out; lung disease; idiopathic pulmonary fibrosis; IPF; deupirfenidone; LYT-100; Sven Dethlefs; phase 3 trial
XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration
XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties
Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift
Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition
Eisai Adopts Elix Discovery Platform to Accelerate AI-Driven Drug Development
Eisai; Elix Discovery; AI drug discovery; federated learning; pharmaceutical innovation; joint research; Japan; DAIIA initiative
Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon
Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon
Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration
Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry
Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns
Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot
Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines